Improved RPLC determination of acyclovir using hexylamine as silanol masking agent

被引:23
作者
Caamaño, MM [1 ]
García, LV [1 ]
Elorza, B [1 ]
Chantres, JR [1 ]
机构
[1] Univ Complutense Madrid, Fac Pharm, Dept Pharmaceut Phys Chem, E-28040 Madrid, Spain
关键词
acyclovir; liposome; reversed-phase HPLC;
D O I
10.1016/S0731-7085(99)00166-1
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The aim of the present work is to improve the sensitivity in the RPLC determination of acyclovir [9-(2-hydroxy ethoxymethyl) guanine] (ACV) and guanine, the major impurity Of the drug synthesis and one of the compounds found in the chemical degradation process of ACV. The method was applied to the quantification of drug in liposomal formulations. The most important problem for RPLC analysis of both compounds are their high pK(a) values, mainly guanine, and the interaction with reactive silanol groups in the stationary phase. In order to avoid these problems there are four basic strategies: (i) ionic pair reagents, (ii) deactivated silica columns, (iii) polymeric based columns and (iv) silanol masking agents. A validation protocol was followed to develop the analytical method, using a Spherisorb ODS (250 x 4.6 mm i.d.) analytical column, with a mobile phase of 95% aqueous phosphate buffer (pH 3.0) and 5% HPLC methanol pumped isocratically at 1.3 mi min(-1), with ultraviolet: detection at 254 nm. The results showed a high reproducibility in retention time value, with R.S.D. of 2.37% for ACV and 0.32% for guanine. The lowest concentration levels assayed, 0.15 mu g ml(-1) for guanine and 1 mu g ml(-1) for ACV, showed good R.S.D, in the quantification parameter (peak area) 11.0% (guanine) and 9.64% (ACV) (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:619 / 624
页数:6
相关论文
共 15 条
[1]  
*AV POL LIP INC, 1994, CAT
[2]   Stability of liposomal formulations: action of amphiphilic molecules [J].
Elorza, MA ;
Elorza, B ;
Chantres, JR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 158 (02) :173-183
[3]  
GASOLOPEZ AI, 1996, J CHROMATOGR SCI, V93, P253
[4]  
GIAMMONA G, 1995, J CONTROL RELEASE, V33, P261, DOI 10.1016/0168-3659(94)00091-8
[5]  
GILMAN AG, 1996, PHARM BASIS THERAPY
[6]   Validation of bioanalytical chromatographic methods [J].
Hartmann, C ;
Smeyers-Verbeke, J ;
Massart, DL ;
McDowall, RD .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 17 (02) :193-218
[7]   THE EFFECTS OF TYPE-B SILICA AND TRIETHYLAMINE ON THE RETENTION OF DRUGS IN SILICA-BASED REVERSE-PHASE HIGH-PERFORMANCE CHROMATOGRAPHY [J].
HILL, DW ;
KIND, AJ .
JOURNAL OF LIQUID CHROMATOGRAPHY, 1993, 16 (18) :3941-3964
[8]   THE IONIZATION PROPERTIES OF ACYCLOVIR AND DEOXYACYCLOVIR [J].
KRISTL, A ;
MRHAR, A ;
KOZJEK, F .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 99 (01) :79-82
[9]   Polymorphism and pseudopolymorphism: Influencing the dissolution properties of the guanine derivative acyclovir [J].
Kristl, A ;
Srcic, S ;
Vrecer, F ;
Sustar, B ;
Vojnovic, D .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 139 (1-2) :231-235
[10]  
Leach D. C., 1988, LC GC N AM, V6